GO:0060684 epithelial-mesenchymal cell signaling: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060684 (epithelial-mesenchymal cell signaling) is defined as any process that results in the transfer of information from an epithelial cell to a mesenchymal cell where it is interpreted.
• This signaling process is a core driver of epithelial-mesenchymal transition (EMT), a conserved program that converts polarized epithelial cells into motile mesenchymal cells.
• Key signaling pathways include TGF-beta, Wnt, Notch, Hedgehog, and receptor tyrosine kinase cascades, which converge on transcriptional reprogramming.
• Dysregulated epithelial-mesenchymal cell signaling contributes to cancer invasion, metastasis, fibrosis, and chronic inflammatory diseases such as chronic rhinosinusitis.
• CD44 and other cell-surface markers are functionally linked to EMT-associated signaling and cancer progression.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of epithelial-mesenchymal signaling genes.
Description
Epithelial-mesenchymal cell signaling (GO:0060684) describes the directed transfer of information from an epithelial cell to a mesenchymal cell, where that information is interpreted to produce a cellular response. This ontology term captures a fundamental mode of intercellular communication that operates during development, tissue repair, and disease progression. Unlike generic signal transduction terms, GO:0060684 specifically requires an epithelial source and a mesenchymal recipient, making it central to understanding how tissue architecture and cell identity are coordinated. The process is best known for its role in epithelial-mesenchymal transition (EMT), a program in which epithelial cells acquire mesenchymal traits such as increased motility and invasiveness. EMT is not a single event but a spectrum of transitional states, and epithelial-mesenchymal signaling provides the extracellular cues that initiate and sustain these state changes. In cancer, epithelial-mesenchymal cell signaling is a major mechanism of tumor cell plasticity, enabling cells to detach, invade, and seed distant metastases. Beyond oncology, the same signaling logic underlies fibrotic remodeling and chronic inflammatory airway disease, where epithelial-derived signals reprogram mesenchymal cells. Because the term is defined by directionality and cell-type context, researchers studying GO:0060684 must combine pathway analysis with cell-type-resolved models. This article synthesizes the QuickGO definition with verified PubMed literature to provide a research-grade overview of the mechanisms, genes, diseases, and experimental methods associated with epithelial-mesenchymal cell signaling.
epithelial-mesenchymal cell signaling At A Glance
| GO ID | GO:0060684 |
|---|---|
| GO term | epithelial-mesenchymal cell signaling |
| Ontology | biological_process |
| Synonym | epithelial-mesenchymal cell signalling |
| Definition | Any process that results in the transfer of information from an epithelial cell to a mesenchymal cell where it is interpreted. |
| Major function | Coordinates epithelial-to-mesenchymal communication during EMT, development, repair, and disease. |
| Key pathways | TGF-beta, Wnt, Notch, Hedgehog, RTK signaling. |
| Disease relevance | Cancer metastasis, fibrosis, chronic rhinosinusitis. |
| Research models | CRISPR KO, point mutation, knock-in, overexpression, library screening. |
What Is GO:0060684?
In our own words, GO:0060684 (epithelial-mesenchymal cell signaling) is the biological process in which an epithelial cell sends a signal that is received and interpreted by a mesenchymal cell, leading to a change in the mesenchymal cell's behavior or state. The term emphasizes the direction of information flow (epithelial to mesenchymal) and the requirement for interpretation in the recipient cell, distinguishing it from autocrine or general paracrine signaling.
Why Is epithelial-mesenchymal cell signaling Important in Cell Biology?
Epithelial-mesenchymal cell signaling is important because it governs a reversible yet powerful cell-state transition that is essential for embryonic development and tissue repair but is frequently hijacked in disease. In cancer, this signaling axis promotes invasion, metastasis, and intratumor heterogeneity, making it a prime target for therapeutic intervention. In chronic inflammatory diseases such as chronic rhinosinusitis, epithelial dysfunction and EMT contribute to tissue remodeling and persistent inflammation. Understanding GO:0060684 therefore has broad implications for developmental biology, oncology, immunology, and regenerative medicine.
• Drives epithelial-mesenchymal transition (EMT), a central mechanism of cancer metastasis.
• Contributes to intratumor heterogeneity and cancer cell plasticity.
• Mediates fibrotic remodeling in chronic inflammatory diseases.
• Regulates developmental processes such as gastrulation and organogenesis.
• Involves major signaling pathways including TGF-beta, Wnt, Notch, and Hedgehog.
• Is linked to CD44-mediated cancer progression and therapeutic resistance.
• Provides biomarkers and therapeutic targets for metastasis.
• Can be modeled with CRISPR-based gene editing for causal studies.
• Serves as a paradigm for teaching cell biology and signaling.
• Connects epithelial dysfunction to mesenchymal activation in airway disease.
What Happens During epithelial-mesenchymal cell signaling?
Initiation by epithelial-derived signals
In simple terms: Epithelial cells release signals that start the conversation with neighboring mesenchymal cells.
The process begins when epithelial cells secrete or present signaling molecules such as TGF-beta, Wnt ligands, or Notch ligands in response to environmental cues. These epithelial-derived signals are the first step in transferring information to mesenchymal cells, as defined by GO:0060684. In cancer, tumor epithelial cells can also be stimulated by inflammatory mediators, including neutrophil extracellular traps, which drive EMT-associated signaling.
Reception and interpretation in mesenchymal cells
In simple terms: Mesenchymal cells receive the signal and translate it into changes in gene expression.
Mesenchymal cells express receptors that bind epithelial-derived ligands, activating intracellular cascades such as SMAD, beta-catenin, or Notch-dependent transcription. The interpretation of these signals leads to transcriptional reprogramming, including upregulation of mesenchymal markers and downregulation of epithelial adhesion molecules. This step is essential for the directional information transfer that defines GO:0060684.
Convergence on EMT transcriptional programs
In simple terms: Multiple signals converge to switch on the genes that make cells mesenchymal.
Signaling from TGF-beta, Wnt, Notch, and Hedgehog pathways converges on core EMT transcription factors such as SNAI1, SNAI2, TWIST1, and ZEB1. These factors repress epithelial genes like CDH1 and activate mesenchymal genes like VIM and CDH2, driving the phenotypic transition. The Notch pathway in particular has been mechanistically linked to cancer EMT and is a target for therapy.
Feedback and plasticity
In simple terms: The conversation is bidirectional and can change over time, allowing cells to shift states.
Epithelial-mesenchymal signaling is not unidirectional in outcome; mesenchymal cells can send feedback signals that alter epithelial behavior, and cells can occupy hybrid E/M states. This plasticity contributes to intratumor heterogeneity and therapy resistance. CD44 and its variants are associated with EMT plasticity and cancer progression, serving as both markers and functional modulators.
Resolution or persistence in disease
In simple terms: Normally the signal stops, but in disease it can stay on and cause problems.
In development and wound healing, epithelial-mesenchymal signaling is transient and resolves. In chronic diseases such as cancer and chronic rhinosinusitis, persistent signaling leads to sustained EMT, fibrosis, and tissue remodeling. Understanding resolution mechanisms is a key research goal for therapeutic intervention.
Key Genes Involved in GO:0060684 epithelial-mesenchymal cell signaling
The following genes and proteins are central to epithelial-mesenchymal cell signaling and EMT, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFB1 | Secreted ligand that initiates EMT signaling | Target for EMT inhibition studies |
| SMAD2/3 | Intracellular transducers of TGF-beta signals | Key nodes for knockout and point-mutation studies |
| SNAI1 | Transcriptional repressor of E-cadherin | Core EMT regulator for overexpression/KO models |
| SNAI2 | EMT-inducing transcription factor | Studied in cancer invasion |
| TWIST1 | Promotes mesenchymal phenotype | Target for CRISPR KO in metastasis models |
| ZEB1 | Represses epithelial genes, induces EMT | Biomarker and functional target |
| CDH1 | Epithelial adhesion molecule lost during EMT | Knockout validates EMT phenotypes |
| CDH2 | Mesenchymal adhesion molecule upregulated in EMT | Readout for EMT progression |
| VIM | Mesenchymal cytoskeletal marker | Common EMT readout |
| CD44 | Cell-surface receptor linked to EMT and cancer progression | Therapeutic target and marker |
| NOTCH1 | Receptor in Notch signaling pathway | Target for Notch inhibitors in cancer |
| JAG1 | Notch ligand expressed in epithelial cells | Modulates epithelial-mesenchymal communication |
| WNT5A | Non-canonical Wnt ligand | Regulates EMT and motility |
| CTNNB1 | Beta-catenin, mediator of Wnt signaling | Central node for knock-in reporters |
| GLI1 | Hedgehog pathway effector | Linked to EMT in cancer |
| FN1 | Extracellular matrix protein induced in EMT | Marker of mesenchymal state |
| MMP9 | Matrix metalloproteinase promoting invasion | Functional readout of EMT |
How Is epithelial-mesenchymal cell signaling Regulated?
Epithelial-mesenchymal cell signaling is regulated at multiple levels, including ligand availability, receptor expression, and intracellular feedback loops. TGF-beta signaling is controlled by SMAD-dependent and SMAD-independent pathways, with negative feedback via SMAD7 and other inhibitors. Notch signaling is regulated by ligand-receptor interactions and proteolytic cleavage, and its dysregulation is linked to cancer. Inflammatory mediators such as neutrophil extracellular traps can amplify EMT signaling in cancer cells. CD44-mediated signaling also modulates EMT and cancer progression, adding another layer of regulation. These regulatory mechanisms provide multiple entry points for experimental perturbation using CRISPR-based approaches.
epithelial-mesenchymal cell signaling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFB1 | Cancer metastasis, fibrosis | Knockout and overexpression in cancer cell lines |
| CDH1 | Loss promotes EMT and invasion | CRISPR knockout in epithelial cancer cells |
| CD44 | Cancer progression and EMT | Knockdown or knockout in metastasis models |
| NOTCH1 | Cancer EMT and therapy resistance | Point mutation and knockout in tumor models |
| SNAI1 | Metastasis and EMT induction | Overexpression and knockout in cell lines |
Cancer metastasis and intratumor heterogeneity
Epithelial-mesenchymal cell signaling is a major driver of cancer cell plasticity, enabling epithelial tumor cells to acquire invasive mesenchymal traits and metastasize. This signaling contributes to intratumor heterogeneity, which complicates therapy and promotes resistance. Neutrophil extracellular traps can further drive EMT in cancer cells, linking inflammation to metastatic progression. CD44 and its variants are functionally associated with EMT and cancer progression, serving as potential therapeutic targets.
Chronic rhinosinusitis and airway remodeling
In chronic rhinosinusitis, epithelial cell dysfunction and EMT contribute to tissue remodeling and persistent inflammation. Epithelial-mesenchymal signaling in the airway promotes mesenchymal activation and fibrosis, making it a relevant process for understanding disease chronicity.
Fibrosis and tissue remodeling
Persistent epithelial-mesenchymal signaling can lead to fibrosis in multiple organs, as epithelial cells release signals that activate mesenchymal cells to produce extracellular matrix. This process is studied in the context of lung, liver, and kidney fibrosis, where EMT-like transitions are observed.
From epithelial-mesenchymal cell signaling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene block EMT? | CRISPR knockout in epithelial cell lines |
| Does a specific mutation alter signaling output? | Point-mutation knock-in via CRISPR |
| Can a reporter track epithelial-mesenchymal signaling? | Tagged knock-in of pathway components |
| Does overexpression drive mesenchymal phenotype? | CRISPR activation or cDNA overexpression |
| Which genes are essential for EMT? | CRISPR library screening |
| How does signaling change over time? | Live-cell imaging with fluorescent reporters |
How to Study the epithelial-mesenchymal cell signaling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | EMT signature identification |
| Proteomics | Protein abundance and modifications | Pathway mapping |
| Immunofluorescence | Protein localization and markers | EMT phenotyping |
| Live-cell imaging | Dynamic signaling and morphology | Real-time EMT tracking |
| CRISPR knockout | Loss-of-function effects | Causal gene validation |
| CRISPR point mutation | Specific amino acid function | Signaling domain analysis |
| CRISPR knock-in | Reporter or tag integration | Tracking signaling components |
| CRISPR library screening | Pooled gene function | Discovery of EMT regulators |
Transcriptomic profiling
RNA-seq is widely used to measure changes in epithelial and mesenchymal gene expression programs during epithelial-mesenchymal signaling. It can identify pathway activation and transcriptional signatures associated with EMT.
Proteomic and phosphoproteomic analysis
Mass spectrometry-based proteomics can quantify signaling intermediates and post-translational modifications in epithelial and mesenchymal cells. This helps map the molecular events downstream of receptor activation.
Imaging and reporter assays
Live-cell imaging with fluorescent reporters for EMT markers or signaling activity allows real-time tracking of epithelial-mesenchymal communication. Immunofluorescence for E-cadherin, vimentin, and CD44 is commonly used.
Functional perturbation with CRISPR
CRISPR knockout, point mutation, knock-in, and overexpression enable causal testing of genes in epithelial-mesenchymal signaling. Library screening can identify novel regulators of EMT.
How CRISPR Can Be Used to Study GO:0060684 epithelial-mesenchymal cell signaling
Knockout
CRISPR knockout is used to delete genes involved in epithelial-mesenchymal signaling, such as TGFB1, SNAI1, or CDH1, to test their requirement for EMT. Knockout models provide causal evidence linking specific genes to signaling outcomes.
Point Mutation
Point mutations can be introduced into signaling components to dissect domain-specific functions, such as phosphorylation sites in SMAD proteins or cleavage sites in Notch. This approach refines mechanistic understanding beyond simple loss-of-function.
Knock-in
Knock-in of fluorescent reporters or epitope tags allows tracking of epithelial-mesenchymal signaling molecules in live cells. Tagged knock-in models are valuable for imaging and biochemical studies.
Overexpression
Overexpression of EMT transcription factors like SNAI1 or TWIST1 can drive mesenchymal phenotypes and test sufficiency. CRISPR activation or cDNA overexpression is used to model gain-of-function states.
How EDITGENE Supports epithelial-mesenchymal cell signaling Research
Researchers studying epithelial-mesenchymal cell signaling-related genes often need to determine whether a candidate gene is causally involved in EMT, metastasis, or fibrosis. EDITGENE provides CRISPR-based cell model services that enable precise genetic perturbations to answer these questions.
Contact EDITGENE today to design your custom CRISPR model for epithelial-mesenchymal cell signaling research.
Frequently Asked Questions About epithelial-mesenchymal cell signaling
What is epithelial-mesenchymal cell signaling (GO:0060684)?
It is the process by which an epithelial cell transfers information to a mesenchymal cell, where it is interpreted, as defined by GO:0060684.
What genes are involved in epithelial-mesenchymal cell signaling?
Key genes include TGFB1, SMAD2/3, SNAI1, SNAI2, TWIST1, ZEB1, CDH1, CDH2, VIM, CD44, NOTCH1, and CTNNB1.
How does epithelial-mesenchymal cell signaling drive cancer metastasis?
It induces EMT, enabling epithelial tumor cells to become invasive and metastatic, and contributes to intratumor heterogeneity.
What signaling pathways mediate epithelial-mesenchymal cell signaling?
TGF-beta, Wnt, Notch, Hedgehog, and receptor tyrosine kinase pathways are major mediators.
What is the role of CD44 in epithelial-mesenchymal signaling?
CD44 is a cell-surface receptor linked to EMT and cancer progression, serving as a marker and functional modulator.
How is epithelial-mesenchymal cell signaling studied in the lab?
Common methods include RNA-seq, proteomics, immunofluorescence, live-cell imaging, and CRISPR-based perturbation.
Can CRISPR be used to study epithelial-mesenchymal cell signaling?
Yes, CRISPR knockout, point mutation, knock-in, overexpression, and library screening are powerful tools for causal studies.
What diseases are associated with epithelial-mesenchymal cell signaling?
Cancer metastasis, fibrosis, and chronic rhinosinusitis are associated with dysregulated signaling.
What is the difference between EMT and epithelial-mesenchymal cell signaling?
EMT is the cellular program; epithelial-mesenchymal cell signaling is the intercellular communication process that can trigger EMT.
How does Notch signaling contribute to epithelial-mesenchymal cell signaling?
Notch signaling is mechanistically linked to cancer EMT and is a target for therapy.
Conclusion
Epithelial-mesenchymal cell signaling (GO:0060684) is a fundamental biological process that coordinates communication between epithelial and mesenchymal cells, with profound implications for development, tissue repair, and disease. Its dysregulation drives cancer metastasis, fibrosis, and chronic inflammatory conditions, making it a high-priority research area. Advances in CRISPR-based models and multi-omics profiling are accelerating the discovery of causal genes and therapeutic targets within this pathway. Continued research into GO:0060684 will deepen our understanding of cell plasticity and provide new opportunities for intervention in human disease.
References
- 1. Cordani M et al.. 2024. Signaling, cancer cell plasticity, and intratumor heterogeneity.. Cell Commun Signal 22(1):255 PMID: 38702718
- 2. Gonzalez DM et al.. 2014. Signaling mechanisms of the epithelial-mesenchymal transition.. Sci Signal 7(344):re8 PMID: 25249658
- 3. Maddalena M et al.. 2025. Neutrophil extracellular traps as drivers of epithelial-mesenchymal transition in cancer cells.. Front Immunol 16:1655019 PMID: 41142788
- 4. Inan S et al.. 2019. Cell Signaling Pathways Related to Epithelial Mesenchymal Transition in Cancer Metastasis.. Crit Rev Oncog 24(1):47-54 PMID: 31679219
- 5. Shi Q et al.. 2024. Notch signaling pathway in cancer: from mechanistic insights to targeted therapies.. Signal Transduct Target Ther 9(1):128 PMID: 38797752
- 6. Chen C et al.. 2018. The biology and role of CD44 in cancer progression: therapeutic implications.. J Hematol Oncol 11(1):64 PMID: 29747682
- 7. Yuan J et al.. 2023. Epithelial cell dysfunction in chronic rhinosinusitis: the epithelial-mesenchymal transition.. Expert Rev Clin Immunol 19(8):959-968 PMID: 37386882
- 8. Carvalho Leão MH et al.. 2023. Epithelial-to-mesenchymal transition as a learning paradigm of cell biology.. Cell Biol Int 47(2):352-366 PMID: 36411367
